These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 1444880)

  • 1. Double-blind parallel design pilot study of acetyl levocarnitine in patients with Alzheimer's disease.
    Sano M; Bell K; Cote L; Dooneief G; Lawton A; Legler L; Marder K; Naini A; Stern Y; Mayeux R
    Arch Neurol; 1992 Nov; 49(11):1137-41. PubMed ID: 1444880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-blind, placebo controlled study of acetyl-l-carnitine in patients with Alzheimer's dementia.
    Rai G; Wright G; Scott L; Beston B; Rest J; Exton-Smith AN
    Curr Med Res Opin; 1990; 11(10):638-47. PubMed ID: 2178869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term acetyl-L-carnitine treatment in Alzheimer's disease.
    Spagnoli A; Lucca U; Menasce G; Bandera L; Cizza G; Forloni G; Tettamanti M; Frattura L; Tiraboschi P; Comelli M
    Neurology; 1991 Nov; 41(11):1726-32. PubMed ID: 1944900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and neurochemical effects of acetyl-L-carnitine in Alzheimer's disease.
    Pettegrew JW; Klunk WE; Panchalingam K; Kanfer JN; McClure RJ
    Neurobiol Aging; 1995; 16(1):1-4. PubMed ID: 7723928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease.
    Thal LJ; Carta A; Clarke WR; Ferris SH; Friedland RP; Petersen RC; Pettegrew JW; Pfeiffer E; Raskind MA; Sano M; Tuszynski MH; Woolson RF
    Neurology; 1996 Sep; 47(3):705-11. PubMed ID: 8797468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer's disease.
    Tobinick EL; Gross H
    BMC Neurol; 2008 Jul; 8():27. PubMed ID: 18644112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acetyl-L-carnitine in the treatment of mildly demented elderly patients.
    Passeri M; Cucinotta D; Bonati PA; Iannuccelli M; Parnetti L; Senin U
    Int J Clin Pharmacol Res; 1990; 10(1-2):75-9. PubMed ID: 2201659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicentre study of l-alpha-glyceryl-phosphorylcholine vs ST200 among patients with probable senile dementia of Alzheimer's type.
    Parnetti L; Abate G; Bartorelli L; Cucinotta D; Cuzzupoli M; Maggioni M; Villardita C; Senin U
    Drugs Aging; 1993; 3(2):159-64. PubMed ID: 8477148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acetyl-L-carnitine: a drug able to slow the progress of Alzheimer's disease?
    Carta A; Calvani M
    Ann N Y Acad Sci; 1991; 640():228-32. PubMed ID: 1776743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease.
    Small G; Erkinjuntti T; Kurz A; Lilienfeld S
    CNS Drugs; 2003; 17(12):905-14. PubMed ID: 12962529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A neuropsychological test battery for use in Alzheimer disease clinical trials.
    Harrison J; Minassian SL; Jenkins L; Black RS; Koller M; Grundman M
    Arch Neurol; 2007 Sep; 64(9):1323-9. PubMed ID: 17846273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of acetyl-L-carnitine in the treatment of cognitive deficit in chronic alcoholism.
    Tempesta E; Troncon R; Janiri L; Colusso L; Riscica P; Saraceni G; Gesmundo E; Calvani M; Benedetti N; Pola P
    Int J Clin Pharmacol Res; 1990; 10(1-2):101-7. PubMed ID: 2201652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The use of 1-acetylcarnitine in (presenile and senile) Alzheimer's disease. Preliminary results].
    Acierno G
    Clin Ter; 1983 Apr; 105(2):135-45. PubMed ID: 6345054
    [No Abstract]   [Full Text] [Related]  

  • 14. Velnacrine for the treatment of Alzheimer's disease: a double-blind, placebo-controlled trial. The Mentane Study Group.
    Zemlan FP
    J Neural Transm (Vienna); 1996; 103(8-9):1105-16. PubMed ID: 9013398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion.
    Alvarez XA; Mouzo R; Pichel V; Pérez P; Laredo M; Fernández-Novoa L; Corzo L; Zas R; Alcaraz M; Secades JJ; Lozano R; Cacabelos R
    Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):633-44. PubMed ID: 10669911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease.
    Montgomery SA; Thal LJ; Amrein R
    Int Clin Psychopharmacol; 2003 Mar; 18(2):61-71. PubMed ID: 12598816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment trial of oxiracetam in Alzheimer's disease.
    Green RC; Goldstein FC; Auchus AP; Presley R; Clark WS; Van Tuyl L; Green J; Hersch SM; Karp HR
    Arch Neurol; 1992 Nov; 49(11):1135-6. PubMed ID: 1444879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral physostigmine treatment for patients with presenile and senile dementia of the Alzheimer's type: a double-blind placebo-controlled trial.
    Jenike MA; Albert MS; Heller H; Gunther J; Goff D
    J Clin Psychiatry; 1990 Jan; 51(1):3-7. PubMed ID: 2403997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 1-year controlled trial of acetyl-l-carnitine in early-onset AD.
    Thal LJ; Calvani M; Amato A; Carta A
    Neurology; 2000 Sep; 55(6):805-10. PubMed ID: 10994000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of oral physostigmine in Alzheimer's disease.
    Stern Y; Sano M; Mayeux R
    Ann Neurol; 1987 Sep; 22(3):306-10. PubMed ID: 3674795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.